NasdaqCM - Nasdaq Real Time Price USD

Lipocine Inc. (LPCN)

5.07 -0.20 (-3.80%)
At close: April 22 at 4:00 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
-2,850.82
-2,850.82
500.00
16,140.84
--
Cost of Revenue
10,175.25
10,175.25
8,556.89
7,665.56
9,748.47
Gross Profit
-13,026.07
-13,026.07
-8,056.89
8,475.28
-9,748.47
Operating Expense
4,904.89
4,904.89
4,062.49
5,329.78
8,247.80
Operating Income
-17,930.96
-17,930.96
-12,119.38
3,145.50
-17,996.26
Net Non Operating Interest Income Expense
1,366.94
1,366.94
545.48
-135.59
-310.97
Other Income Expense
212.69
212.69
815.94
-3,644.11
-2,657.39
Pretax Income
-16,351.33
-16,351.33
-10,757.96
-634.20
-20,964.62
Tax Provision
0.76
0.76
0.68
0.20
0.20
Net Income Common Stockholders
-16,352.17
-16,352.17
-10,758.64
-634.40
-20,964.82
Average Dilution Earnings
-212.69
-212.69
-565.94
--
--
Diluted NI Available to Com Stockholders
-16,564.86
-16,564.86
-11,324.58
-634.40
-20,964.82
Basic EPS
-3.10
--
-2.06
-0.17
-6.46
Diluted EPS
-3.14
--
-2.15
-0.17
-6.46
Basic Average Shares
5,269.67
--
5,231.68
5,113.80
3,275.77
Diluted Average Shares
5,269.67
--
5,256.17
5,113.80
3,275.77
Total Operating Income as Reported
-17,930.96
-17,930.96
-12,119.38
3,145.50
-17,996.26
Total Expenses
15,080.14
15,080.14
12,619.38
12,995.34
17,996.26
Net Income from Continuing & Discontinued Operation
-16,352.08
-16,352.08
-10,758.64
-634.40
-20,964.82
Normalized Income
-16,520.11
-16,520.11
-11,403.23
2,025.80
-19,024.93
Interest Income
1,366.94
1,366.94
572.58
67.70
75.65
Interest Expense
--
--
27.10
203.29
386.62
Net Interest Income
1,366.94
1,366.94
545.48
-135.59
-310.97
EBIT
-16,351.33
-16,351.33
-10,730.86
-430.91
-20,578.00
EBITDA
-16,322.67
-16,322.67
-10,721.40
-430.53
-20,574.45
Reconciled Cost of Revenue
10,175.25
10,175.25
8,556.89
7,665.56
9,748.47
Reconciled Depreciation
28.66
28.66
9.45
0.38
3.55
Net Income from Continuing Operation Net Minority Interest
-16,352.08
-16,352.08
-10,758.64
-634.40
-20,964.82
Total Unusual Items Excluding Goodwill
212.69
212.69
815.94
-3,644.11
-2,657.39
Total Unusual Items
212.69
212.69
815.94
-3,644.11
-2,657.39
Normalized EBITDA
-16,535.36
-16,535.36
-11,537.34
3,213.58
-17,917.06
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
44.66
44.66
171.35
-983.91
-717.49
12/31/2020 - 10/22/2013

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

TRVN Trevena, Inc.
0.3702
+5.17%
 
ATHE Alterity Therapeutics Limited
2.1300
+3.40%
 
NRXP NRx Pharmaceuticals, Inc.
3.0000
-1.32%
 
CNTB Connect Biopharma Holdings Limited
1.3500
-10.00%
 
CDTX Cidara Therapeutics, Inc.
0.5139
-24.54%
 
TCON TRACON Pharmaceuticals, Inc.
1.8200
-7.14%
 
VTVT vTv Therapeutics Inc.
24.44
+1.85%
 
VINC Vincerx Pharma, Inc.
0.8690
+2.24%
 
CRDF Cardiff Oncology, Inc.
4.3600
+0.23%
 
ASLN ASLAN Pharmaceuticals Limited
0.4550
-11.13%